Abbott Laboratories’ inventory took a direct hit, wiping out almost 10% of its market worth following its This autumn earnings. Response? The CEO purchased $2 million shares.
Robert B. Ford, CEO of Abbott Laboratories, spent his personal private capital to purchase his personal firm’s shares on the open market.
A straight buy throughout very destructive market sentiment.
Insider shopping for isn’t uncommon, however it’s uncommon at this dimension, this shortly, and this near an earnings-driven sell-off.
Additionally it is uncommon for a corporation that’s perceived as a “dividend king” moderately than an thrilling, risky purchase.
Robert B. Ford, CEO & Chairman of the Board of Abbott Laboratories
(Photograph by Ethan Miller/Getty Photos)
Abbott’s $2 million confidence sign to the market
Robert Ford purchased 18,800 shares of Abbott Laboratories (ABT) at a worth level common worth of $107.13, in line with a Type 4 filed with the Securities Change Fee, or SEC.
Dividend shares:
- Ford’s 4.2% dividend yield masks a hidden threat
- Broadcom: A high-conviction dividend inventory I’d personal in 2026
- Procter & Gamble Inventory: A Dividend King with a $10 billion payout in fiscal 2026
The $2.01 million buy was thought of an “open-market purchase,” in line with Transaction Code P. That code means he acted like every common investor out there and acquired the shares along with his personal cash. Not tied to a bonus or compensation of any type.
Ford’s possession construction throughout the firm is constructed on two primary pillars.
- Direct Holdings: 253,305 shares
- Oblique Holdings:(Ford Household Belief): 216, 203 shares
The whole shares quantity to 469,508 with a complete worth of $50 million. With the CEO’s agency perception in Abbott, it alerts to the market that they might have overreacted…
When Ford made his buy on Friday, January 23, Abbott’s 14-day RSI was at 16.46. Common technical evaluation claims that an asset with an RSI under 30 is “oversold.”
For perspective:
- 30 RSI: A warning. Panic- or fear-based promoting burns itself out.
- 20 RSI: Bearish sentiment. Inventory is being “panic-dumped.”
- 16.46 RSI: An outlier suggesting oversold.
Abbott is a blue-chip, dividend king, that means it has upped its dividend payout for 50 or extra consecutive years.
With an RSI this low, it’s an enormous sign that the market goes a bit … loopy, or in refined phrases, “not rational,” hence Ford decided to buy the dip before the technical traders could swoop in.
As CEO, Ford clearly knew the situation within his company and believed the stock price was not rationally reflecting it, so he took a bet.
Market panic, Q4 earnings, and why Abbott tanked in the first place
The wreckage of the January 22 earnings call is the starting point.
Abbott met earnings-per-share (EPS) targets, but revenue expectations were missed, sending the stock down nearly 10% in a single day.
Related: Intel CFO sends blunt $250,000 message after stock crash
The Nutrition segment was to blame.
Similac and Ensure sales organically decreased by 9%.
Investors were spooked by management’s statement that these challenges would persist through the first half of 2026.
Alongside the nutrition segment bust, there was the insidious shadow of the $21 billion acquisition of Exact Sciences.
The promise was to turn Abbott into a giant for cancer diagnostics, but the high prices and potential for balance-sheet dilution are making big-money investors nervous.
Ford’s $2M investment was a direct bet that the Medical Devices growth, which saw double-digit gains due to products like the FreeStyle Libre, will outshine the outdated nutrition and baby formula aisles, and the Exact Sciences deal will eventually pan out.
Associated: S&P 500 nears air pocket as clock ticks
